Stuart Henderson
Vice President of Corporate Development and Investor Relations
Replay available
Passage Bio, Inc. (PASG) Q2 2022 Earnings Call
Passage Bio, Inc. (NASDAQ: PASG) Q2 2022 earnings conference call, held 2022-08-04. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Mark Forman
Chief Medical Officer
Simona King
Chief Financial Officer
Chip Cahill
Interim Chief Executive Officer
Brendan Smith
Analyst, Cowan
Nina Trudeau Garage
Analyst, Citi
Laura Chico
Analyst, Wedbush
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Passage Bio, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.029 -- 00:00:04.570 Good morning and welcome to the Passage Bio Second Quarter 2022 00:00:04.570 -- 00:00:08.632 Financial and Operating Results Conference Call. 00:00:08.632 -- 00:00:12.353 At this time, all participants are on a listen-only mode. 00:00:12.353 -- 00:00:16.894 Following the formal remarks, we will open the call up for your questions. 00:00:16.894 -- 00:00:21.876 Please be advised that this call is being recorded at the company's request. 00:00:21.876 -- 00:00:26.697 Now I'd like to turn the call over to Stuart Henderson, Vice President of Corporate Development 00:00:26.697 -- 00:00:31.338 and Investor Relations. Stuart, please proceed. 00:00:34.039 -- 00:00:38.002 Thank you, Operator. This morning, we issued a press release that outlines the topics 00:00:38.002 -- 00:00:42.646 we plan to discuss today. This release is available on the Passage Bio website under 00:00:42.646 -- 00:00:46.629 the Press Releases and Statements section of Investors & News. 00:00:46.629 -- 00:00:51.252 On today's call, Chip Cahill, Interim Chief Executive Officer, will review our second 00:00:51.252 -- 00:00:54.255 quarter 2022 and recent business highlights. 00:00:54.255 -- 00:00:58.658 Mark Forman, our Chief Medical Officer, will review our clinical programs, and Simona 00:00:58.658 -- 00:01:03.841 King, our Chief Financial Officer, will review our second quarter 2022 financial results. 00:01:04.557 -- 00:01:08.878 Before we begin, please note that today's call may include a number of forward-looking 00:01:08.878 -- 00:01:13.880 statements, including but not limited to comments on our expectations about timing and 00:01:13.880 -- 00:01:18.341 execution of anticipated milestones, including the initiation of clinical trials and 00:01:18.341 -- 00:01:23.603 t...